176 related articles for article (PubMed ID: 22869929)
1. Deletion of Abcg2 has differential effects on excretion and pharmacokinetics of probe substrates in rats.
Huang L; Be X; Tchaparian EH; Colletti AE; Roberts J; Langley M; Ling Y; Wong BK; Jin L
J Pharmacol Exp Ther; 2012 Nov; 343(2):316-24. PubMed ID: 22869929
[TBL] [Abstract][Full Text] [Related]
2. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
[TBL] [Abstract][Full Text] [Related]
3. N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk.
Wang L; Leggas M; Goswami M; Empey PE; McNamara PJ
Drug Metab Dispos; 2008 Dec; 36(12):2591-6. PubMed ID: 18799806
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
Zaher H; Khan AA; Palandra J; Brayman TG; Yu L; Ware JA
Mol Pharm; 2006; 3(1):55-61. PubMed ID: 16686369
[TBL] [Abstract][Full Text] [Related]
5. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2.
Wang X; Morris ME
Drug Metab Dispos; 2007 Feb; 35(2):268-74. PubMed ID: 17093006
[TBL] [Abstract][Full Text] [Related]
6. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin.
Merino G; Jonker JW; Wagenaar E; van Herwaarden AE; Schinkel AH
Mol Pharmacol; 2005 May; 67(5):1758-64. PubMed ID: 15709111
[TBL] [Abstract][Full Text] [Related]
7. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
Zhang D; Frost CE; He K; Rodrigues AD; Wang X; Wang L; Goosen TC; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):906-15. PubMed ID: 23386703
[TBL] [Abstract][Full Text] [Related]
8. The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.
Adkison KK; Vaidya SS; Lee DY; Koo SH; Li L; Mehta AA; Gross AS; Polli JW; Lou Y; Lee EJ
Br J Clin Pharmacol; 2008 Aug; 66(2):233-9. PubMed ID: 18429968
[TBL] [Abstract][Full Text] [Related]
9. Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line.
Staud F; Vackova Z; Pospechova K; Pavek P; Ceckova M; Libra A; Cygalova L; Nachtigal P; Fendrich Z
J Pharmacol Exp Ther; 2006 Oct; 319(1):53-62. PubMed ID: 16809480
[TBL] [Abstract][Full Text] [Related]
10. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
Merino G; van Herwaarden AE; Wagenaar E; Jonker JW; Schinkel AH
Mol Pharmacol; 2005 May; 67(5):1765-71. PubMed ID: 15722455
[TBL] [Abstract][Full Text] [Related]
11. In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
Matsuda Y; Konno Y; Hashimoto T; Nagai M; Taguchi T; Satsukawa M; Yamashita S
Drug Metab Dispos; 2013 Aug; 41(8):1514-21. PubMed ID: 23686319
[TBL] [Abstract][Full Text] [Related]
12. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
[TBL] [Abstract][Full Text] [Related]
13. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin.
Hirano M; Maeda K; Matsushima S; Nozaki Y; Kusuhara H; Sugiyama Y
Mol Pharmacol; 2005 Sep; 68(3):800-7. PubMed ID: 15955871
[TBL] [Abstract][Full Text] [Related]
14. Decreased hepatic breast cancer resistance protein expression and function in multidrug resistance-associated protein 2-deficient (TR⁻) rats.
Yue W; Lee JK; Abe K; Sugiyama Y; Brouwer KL
Drug Metab Dispos; 2011 Mar; 39(3):441-7. PubMed ID: 21106720
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.
Karibe T; Hagihara-Nakagomi R; Abe K; Imaoka T; Mikkaichi T; Yasuda S; Hirouchi M; Watanabe N; Okudaira N; Izumi T
Pharm Res; 2015 May; 32(5):1634-47. PubMed ID: 25380981
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of chrysin on nitrofurantoin pharmacokinetics mediated by intestinal breast cancer resistance protein in rats and mice.
Kawase A; Matsumoto Y; Hadano M; Ishii Y; Iwaki M
J Pharm Pharm Sci; 2009; 12(2):150-63. PubMed ID: 19732493
[TBL] [Abstract][Full Text] [Related]
17. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.
An G; Gallegos J; Morris ME
Drug Metab Dispos; 2011 Mar; 39(3):426-32. PubMed ID: 21139040
[TBL] [Abstract][Full Text] [Related]
18. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.
Adkison KK; Vaidya SS; Lee DY; Koo SH; Li L; Mehta AA; Gross AS; Polli JW; Humphreys JE; Lou Y; Lee EJ
J Pharm Sci; 2010 Feb; 99(2):1046-62. PubMed ID: 19569219
[TBL] [Abstract][Full Text] [Related]
19. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat.
Zamek-Gliszczynski MJ; Hoffmaster KA; Humphreys JE; Tian X; Nezasa K; Brouwer KL
J Pharmacol Exp Ther; 2006 Oct; 319(1):459-67. PubMed ID: 16857726
[TBL] [Abstract][Full Text] [Related]
20. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
